We prospectively examined stool specimens for enteric viruses in 75 stem cell transplant recipients (autologous 48, allogeneic 27) to determine the frequency and significance of these infections. Only six patients (8%) had a positive isolate. Five of these were allograft recipients (18%) compared to one autograft recipient (2%) (P = 0.02). Unrelated donor BMT recipients were at the highest risk for a viral isolate (OR = 10.5). Adenovirus was the commonest isolate (four patients). One patient each had an echovirus, enterovirus and small round structured virus identified. No correlation was found between the severity of gastro-intestinal symptoms and detection of a viral pathogen. There was no correlation with GVHD or CMV status. The only risk factor identified for isolation of an enterovirus was allogeneic BMT from an unrelated donor. There was a negative correlation with PBSC grafts. All the patients infected with an enteric virus had concomitant infection with other pathogens, compared to only 18% of uninfected patients (P = 0.001). The non-relapse mortality of the infected patients was 50% and only 7% in the uninfected patients (P = 0.01, OR = 12.5), although the isolated virus was the direct cause of death in one patient only. This study indicates a low rate of enteric virus isolation in recipients of PBSC grafts, both autologous and allogeneic. However, unrelated donor BMT is associated with a higher risk of enteric virus infection and an adverse outcome. Bone Marrow Transplantation (2000) 25, 277-282.
Infectious complications are a major cause of mortality and morbidity in stem cell transplant recipients. Systemic bacterial and fungal infections and infections caused by herpes viruses have been implicated during both early and late post-transplant periods. Enteric viruses such as adenoviruses [1] [2] [3] and enteroviruses [4] [5] [6] have been reported to cause both localised and systemic disease in these patients, but only a few prospective studies have addressed the role of enteric pathogens in causing post-transplant infection and disease. Viral pathogens have been isolated from stools of both autologous and allogeneic BMT recipients. 7 Infections with enteric viruses have also been reported to be associated with a higher mortality rate in allograft recipients. 8 BMT recipients are often infected with more than one micro-organisms. The clinical significance of such infections are often unclear and case reports linking a viral infection with particular symptoms in this patient group may be unhelpful. In this context, establishing causality is difficult. It is only through prospective surveillance that a firmer link between infection and disease can be made.
We have prospectively evaluated 75 stem cell transplant recipients, both autologous and allogeneic, in order to determine the frequency and significance of isolation of enteric viruses from stool specimens during the posttransplant period.
Patients and methods

Study population
We prospectively evaluated 75 patients who were hospitalised in the BMT unit at the Birmingham Heartlands Hospital for stem cell transplantation between May 1997 and November 1998. Forty-eight patients received an autologous transplant. Twenty-seven had an allogeneic graft, 18 from matched sibling donors and nine from unrelated donors (UD). Thirty-two patients had total body irradiation (TBI) as a part of the conditioning regimen. All patients were nursed in single rooms with high efficiency particulate air (HEPA) filters.
Anti-microbial prophylaxis was with oral fluconazole, aciclovir and ciprofloxacin. In addition, allogeneic transplant recipients received metronidazole. Cyclosporin A and short-course methotrexate were given as GVHD prophylaxis in all except two patients who received cyclosporin A alone. Campath 1H was given from day −5 to day + 4 to recipients of unrelated donor grafts. Oral co-trimoxazole was initiated in allograft recipients when the neutrophil count was greater than 1.0 × 10 9 /l. Allograft recipients at risk of CMV disease (recipient or donor positive for CMV IgG) received pre-emptive therapy with ganciclovir with or without foscarnet based on a PCR assay. 9 CMV sero-negative patients received blood products negative for CMV infection.
Study design
Stool specimens for virus study and routine microbiology were obtained from patients before transplant and weekly during the hospital stay. Thereafter, the samples were obtained for virology every 14 days until day 100 or when symptomatic with gastro-intestinal or respiratory symptoms or hospitalised for any reason. Further bacterial and fungal studies were carried out only when symptomatic or hospitalised.
Laboratory methods
Stool specimens were screened for the enteric viruses by electron microscopy (EM) and virus culture. For EM, a 50% v/v suspension of each faecal sample was prepared in phosphate-buffered saline and placed on EM grids with strengthened formvar membranes. The grids were stained with 2.5% phosphotungstic acid and examined using a Jeol 100CX electron microscope with an accelerating voltage of 80 kV. For culture, 0.2 ml of the supernatant prepared from centrifugation of a 10% v/v suspension of faeces in PBS containing antibiotics was added to monolayers of Rhesus monkey kidney and Hep 2 cells. The cells were incubated at 33°C for 14 days and examined thrice weekly for cytopathic effects. Adenovirus isolates were serotyped by neutralisation assay. Enteroviruses were typed using pooled fluorescein-conjugated monoclonal antibodies (Chemicon International, Temecula, CA, USA).
Specimens for bacteriological and fungal investigations were processed using standard methods of microscopy, culture and sensitivity testing. Clostridium difficile toxin detection in stool samples was performed using cell culture cytotoxicity assay (Hep2 cells) for toxin B, equivocal results from this initial assay being confirmed or refuted by toxin A enzyme-linked immunoassay. In this study we defined infection as the identification of a virus from a stool sample.
The presence of a virus together with appropriate symptoms in the absence of any other recognisable cause is termed symptomatic infection or disease. In the absence of symptoms it is termed asymptomatic infection. All patients were evaluated for gastrointestinal symptoms. Diarrhoea, vomiting and upper gastrointestinal (GI) mucositis were graded according to WHO toxicity criteria. Documented infections at other sites were also noted. GVHD was graded according to standard criteria.
Statistical methods
Univariate analysis was performed to study the association between a positive stool isolate and the risk factors. P values were calculated using Fisher's exact test. A multiple logistic regression model was fitted to the data using a stepwise approach, in order to determine the impact of these variables on the isolation of stool pathogens. A similar model was used to analyse the effect of these variables on mortality.
Results
A total of 537 stool samples were investigated. The median number of specimens per patient was seven. Enteric viruses were identified in stool specimens from six patients (8%) after transplant (Table 1) . None had a positive isolate prior to transplant. The commonest viral isolate was adenovirus (four). Other viruses identified were echovirus (one), enterovirus (one) and small round structured virus (SRSV) (one). All the viruses except SRSV were cultured. There was no correlation with isolation of viruses and the severity of gastro-intestinal symptoms ( Table 1 ). The median number of stool samples with a positive isolate was two (one to 14). One patient had more than one virus isolate (adenovirus and SRSV).
The adenovirus isolates were all of serotype 2. The median time of isolation of adenovirus was 100 days (15-202) ( Table 2) . One patient had severe gastro-enteritis but cleared the virus after withdrawal of immunosuppression. Another patient had only mild diarrhoea at presentation but persistently excreted adenovirus in stool for 2 months. The virus was not detected 4 weeks after cessation of cyclosporin A and infusion of donor lymphocytes for relapsed leukaemia (manuscript submitted for publication). A recipient of an UD transplant had asymptomatic excretion of adenovirus in stool 32 weeks after transplantation before succumbing to fulminant adenovirus hepatitis not responding to ribavirin. 10 He was being treated for GVHD at the time. He also excreted SRSV 25 days post transplant associated with diarrhoea in the absence of any other pathogen. Ninety-three days following an UD allograft, a similar patient presented with severe pneumonia due to multiple respiratory viruses within 2 weeks of the isolation of an adenovirus. Another UD BMT recipient had an enterovirus isolated from stool 145 days post transplant. She had a seizure at the same time, but the CSF examination was negative for enterovirus by RT-PCR and culture. The enterovirus could not be typed with the limited range of pooled monoclonal antibodies. She was receiving treatment for gut GVHD with methylprednisolone at the time of isolation and succumbed to aspergillus pneumonia within a fortnight. The only autograft recipient who had a positive virus isolate had very delayed neutrophil recovery on day 55 post transplant. An echovirus was isolated from her stool 6 weeks after transplant. This was associated with severe diarrhoea in the absence of other pathogens and resolved spontaneously. Five of these six patients infected with an enteric virus had neutrophil engraftment beyond 14 days (neutrophils Ͼ0.5 × 10 9 /l median 16.5 days (range 12-55)). On risk factor analysis (Table 3) , the isolation of a virus in the stool was not related to the age or sex of the patients, conditioning with TBI, CMV seropositivity or Ͼgrade 1 GVHD. Five (18%) of 27 allograft recipients had a virus isolated compared to one (2%) of 48 autograft recipients (P = 0.02). Four (23%) of 17 patients transplanted with a bone marrow graft were infected with an enteric virus compared to two (3.5%) of 58 PBSC transplants (P = 0.02). Three patients (50%) with a viral isolate had grafts from an unrelated donor (P = 0.02). On multiple logistic regression analysis, the most significant variable for the development of enteric viral infection was an unrelated donor bone marrow graft (OR 4.7, P Ͻ 0.05). Autograft recipients were at a lower risk (OR 0.10) and among allograft recipients, BMT (matched sibling or UD) recipients were at a greater risk compared with those receiving PBSCT (OR 8.5). Thus, 279 Table 1 Characteristics of patients with and without a virus isolate allogeneic BMT recipients were at the highest risk of isolation of stool pathogens if they received a UD graft. Concomitant infections with other pathogens were detected in all patients with a positive stool isolate, whereas only 13 (18%) of uninfected patients had a documented concomitant infection (P = 0.0001). The mortality in this group of patients was significantly higher. Four of six patients (66%) had an early mortality compared to seven (10%) of 69 patients without a stool isolate (P = 0.003). Three of these six (50%) infected patients died due to infectious causes compared to five (7%) patients not excreting a virus (P = 0.01). In the stepwise multiple logistic regression model, allograft recipients with a viral isolate in the stool had the highest risk of mortality.
Patients with a virus isolate (%) Patients without a virus isolate (%) P value (odds ratio)
Discussion
Infections in stem cell transplant recipients are broadly related to the kinetics of immune reconstitution. During the initial aplastic phase, bacterial and fungal infections dominate depending on severity and duration of neutropenia. Subsequent infections are often due to reactivation of latent viruses, usually of the herpes virus family. However, enteric viruses such as adenovirus, rotavirus and enteroviruses have been reported to cause serious infection in these patients. [1] [2] [3] [4] [5] [6] The role of enteric viruses has been prospectively investigated in only a few studies to date. 7, 8 Previous studies have indicated a high incidence of viral gastro-enteritis in bone marrow transplant recipients. Yolken et al 8 first reported the high incidence of infective gastro-enteritis in allogeneic BMT patients. Thirty-one (40%) of 78 patients were infected with an enteric pathoBone Marrow Transplantation gen. Adenovirus and C. difficile were the commonest isolates, other isolates being rotavirus and coxsackievirus. Another report demonstrated a similar incidence (20%) of viral gastro-enteritis in both autologous and allogeneic BMT. 7 Again, adenovirus was the commonest isolate (11 of 94 patients).
The incidence of viral gastro-enteritis in our study is lower than in previous studies. It was very uncommon in PBSC autografts and matched sibling PBSC allografts. Viral infections occurred at a median of 19-47 days after transplant in the previously reported studies. 7, 8 We isolated the viruses at a median of 93 days and mostly from unrelated donor BMT recipients. Immune reconstitution is reported to be more rapid in patients receiving PBSC grafts 11, 12 and this might have been responsible for the lower incidence of virus isolates. Conversely, the association with UD bone marrow grafts might be related to the impaired immune reconstitution in these patients, as the grafts were T cell depleted. In addition, the two allogeneic PBSCT recipients with adenovirus infections had received immunosuppressive conditioning with fludarabine and Campath. Thus, all the allogeneic transplant recipients with a gastro-intestinal virus isolate had a T cell-depleted UD graft or had received additional immunosuppression.
The role of immunosuppression in the genesis of adenovirus infections is well recognised [1] [2] [3] and in parallel with the previous reports adenovirus was the commonest isolate in our study. Adenovirus has been increasingly identified as a serious pathogen in BMT recipients. Five to 20% of patients develop adenovirus infections following a transplant and about 6.5% develop invasive disease. [1] [2] [3] The incidence is reported to be higher in T cell-depleted and unrelated allografts, with 50% mortality. 3 Adenoviruses, types 40 and 41 are predominantly isolated in patients with gastro-enteritis. 13 Types 2 and 31 have also been isolated, although to a lesser extent. 13 All the adenovirus isolates in our study were type 2, which belongs to the subgenus C. Adenovirus type 2 is a common subtype isolated in BMT recipients, together with type 31 (subgenus A) and type 11 (subgenus B). 10, 13 They have been responsible for gastroenteritis, pneumonia and liver disease in these patients. 10, 13 Only one of our patients excreting adenovirus had significant GI symptoms. Another patient developed fulminant adenovirus hepatitis. The other two patients had no gastrointestinal symptoms despite isolation of the virus. It is believed that tonsils, adenoids and other lymphoid tissues are the possible source of latent adenovirus infections 14 and reactivation at these sites might be the source for adenovirus in the GI tract in these patients without gastro-intestinal symptoms. Withdrawal of immunosuppression and DLI in the two patients with adenovirus infection resulted in improvement, in contrast to the fatal outcome in the other patients on continued immunosuppression. We did not detect adenovirus infections in autograft recipients, in contrast to a previous study reporting a 12% incidence in ABMT patients. 7 This might be related to use of PBSC grafts in our patients resulting in faster immune recovery. Another study has reported adenovirus infections in only 1.1% of paediatric autologous transplant recipients. 15 Enteroviruses comprise polioviruses, coxsackie A and B viruses, echoviruses and recently recovered types, numbered 68-71. 16 
Disseminated echovirus and other
Bone Marrow Transplantation enterovirus infections have been reported following BMT. [4] [5] [6] The role of cell-mediated immunity in the genesis of enteroviral infections is not clear. It is predominantly observed in patients with defects in the humoral arm of the immune system manifesting often as meningoencephalitis. 16 Enteroviruses were isolated in a small number of patients in the previous studies. 7, 8 The enterovirus we isolated in the patient with CNS symptoms could not be typed. As it was not isolated from the CSF, its contribution to the central nervous system events remains dubious. However, this patient was being treated for gut GVHD following a second transplant and was expected to have poor immune function. The echovirus was isolated in an autograft recipient who had an unusual delay in engraftment. She had severe diarrhoea at the time the echovirus was isolated from her stool. The other notable feature in this study has been the absence of rotavirus isolates. Rotavirus infections have been reported in 8.5-12% of BMT patients. 7, 8 Apart from GI symptoms, rotaviruses may cause respiratory symptoms. 8 As this study spanned 18 months, it is unlikely that the seasonal variations of rotavirus or other enteroviruses have been missed. The lower incidence of viral isolates in our study might be related to the use of more specific methods of detection. Previous studies used a latex agglutination assay reported to produce false positive results. 17 As rotavirus can survive in a conducive environment for several days and infected patients excrete more than 10 12 particles/g of faecal matter 7 it is unlikely that infections were missed using EM detection methods. Other enteric viruses have been reported to cause diarrhoea in patients with AIDS. 18 However, their significance in the BMT population remains unclear. We detected SRSV, which belongs to the calicivirus family, in one of our patients with diarrhoea. This is a common cause of hospital outbreaks of gastro-enteritis. 18, 19 However, none of the other patients had a similar isolate. The same patient later excreted adenovirus as well. Again, unlike the previous studies, 7,8 multiple enteric virus isolation was uncommon in our study. Acute GVHD and the use of TBI have been identified as risk factors for adenovirus infections, [1] [2] [3] 15 and enteric virus isolation. 7 We did not find any significant association with either.
In addition, CMV sero-positivity or reactivation did not influence the chance of having a positive stool isolate. Despite a lack of correlation with GVHD or CMV seropositivity in these patients, there was a higher mortality in the infected patients. This parallels the study by Yolken et al 8 where 13 (59%) of the patients infected with a viral pathogen died, six patients dying within 11 days of the first positive culture. They implicated the intestinal pathogens as a direct cause of mortality although the evidence was not compelling. In our study, three patients died within 14 days of the first isolation of a virus. Enteric viruses were not a direct cause of their death, except in one patient. All patients had infections with other pathogens detected during this course and three of them succumbed to fulminant infections. Although there is a risk of overstatement in view of the small number of patients having a virus recovered from the stool, these patients were probably more immunocompromised than the remainder. This was evidenced by the other fungal and viral infections occurring in these patients subsequently or simultaneously. Thus, detection of enteric viruses on routine stool surveillance may suggest inadequacy of immune recovery. Interestingly, in both the patients with adenovirus infections following non-myeloablative conditioning, the infection was controlled by the withdrawal of immunosuppression and neither died of infectious causes. In this study, within the constraints of the small numbers, detection of a viral pathogen in the stool was the best predictor of poor outcome in allogeneic transplants. There might be a window period before development of more fatal infections allowing early intervention to reduce the magnitude of iatrogenic immunosuppression in order to prevent more serious infections and early mortality. This might be difficult in the presence of GVHD, but worth bearing in mind in order to strike a balance between the degree of immunosuppression and the risk of fatal infections. This probably indicates that isolation of an enteric virus, particularly an adenovirus, may be a surrogate marker for a poor prognosis in the presence of continued immunosuppression.
On cost analysis, the average cost of the surveillance per patient for the study has been about £200 ($160), which is affordable compared to the total cost of an allogeneic transplant.
In conclusion, our study indicates that isolation of an enteric virus from the stool is uncommon in recipients of unmanipulated PBSC grafts, both autologous and allogeneic. However, there seems to be an increased incidence of virus isolation, usually adenoviruses, in unrelated donor BMT recipients. Although infections with enteric viruses are often asymptomatic, they are associated with a high mortality, compounded usually by other opportunistic infections. If this is confirmed in a larger study in this patient population, there might be a case for developing strategies for promoting better immune recovery in high risk patients as a pre-emptive approach.
